stoxline Quote Chart Rank Option Currency Glossary
  
PainReform Ltd. (PRFX)
0.71  0 (0%)    05-30 16:00
Open: 0.717961
High: 0.73
Volume: 8,346
  
Pre. Close: 0.71
Low: 0.71
Market Cap: 2(M)
Technical analysis
2024-05-30 4:43:50 PM
Short term     
Mid term     
Targets 6-month :  0.99 1-year :  1.13
Resists First :  0.84 Second :  0.97
Pivot price 0.76
Supports First :  0.64 Second :  0.54
MAs MA(5) :  0.7 MA(20) :  0.78
MA(100) :  1.6 MA(250) :  2.79
MACD MACD :  -0.2 Signal :  -0.2
%K %D K(14,3) :  22.3 D(3) :  19.1
RSI RSI(14): 32.6
52-week High :  26.4 Low :  0.41
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ PRFX ] has closed above bottom band by 22.8%. Bollinger Bands are 62.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 19 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.73 - 0.73 0.73 - 0.74
Low: 0.7 - 0.71 0.71 - 0.71
Close: 0.7 - 0.71 0.71 - 0.72
Company Description

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.

Headline News

Wed, 15 May 2024
PainReform Provides Business Update for the First Quarter of 2024 - GlobeNewswire

Wed, 08 May 2024
PainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the ... - GlobeNewswire

Tue, 16 Apr 2024
PainReform Ltd. Launches $4 Million Public Offering - TipRanks.com - TipRanks

Tue, 16 Apr 2024
PainReform Announces Pricing of $4 Million Public Offering - GlobeNewswire

Tue, 09 Apr 2024
PainReform’s PRF-110 Sets New Pain Relief Benchmark - TipRanks

Tue, 09 Apr 2024
PainReform's Non-Opiate Topical Treatment for Post-Surgical - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Shares Out 2 (M)
Shares Float 1 (M)
Held by Insiders 8.8 (%)
Held by Institutions 20.3 (%)
Shares Short 20 (K)
Shares Short P.Month 16 (K)
Stock Financials
EPS -7.14
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.19
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -53.9 %
Return on Equity (ttm) -102.4 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -3.88
Qtrly Earnings Growth 0 %
Operating Cash Flow -7 (M)
Levered Free Cash Flow -4 (M)
Stock Valuations
PE Ratio -0.1
PEG Ratio 0
Price to Book value 0.16
Price to Sales 0
Price to Cash Flow -0.27
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android